Kang J O, Hudak W A, Keller N, Criswell B S
University of Arizona, Tucson 85719.
Clin Chem. 1988 Oct;34(10):1983-6.
We used an enzyme-linked immunosorbent assay to quantify CA-125, a cancer antigen, in serum of patients with endometriosis. Concentrations of CA-125 in 103 patients with untreated endometriosis significantly (P less than 0.005) exceeded those for 31 controls with no evidence of disease: 9.1 (SD 12.3) vs 2.2 (SD 3.2) arb. units/mL. Values for patients with treated endometriosis were lower (2.3, SD 2.6, arb. units/mL, n = 9) than those for patients with untreated endometriosis. The mean concentrations of CA-125 in different stages of untreated endometriosis were 4.8 (SD 4.5), 7.1 (SD 9.9), 9.8 (SD 13.2), and 10.8 (SD 13.0) arb. units/mL for Stages I, II, III, and IV, respectively. The differences between controls and each stage were statistically significant (for all stages: P less than 0.05). We also assayed serum sampled from controls and patients with untreated endometriosis during menstruation (Group A) and during nonmenstruation (Group B). The efficacy of the present assay for concentrations of CA-125 in serum of patients with endometriosis was greater for Group B than for Group A. Evidently, determination of CA-125 in serum by the present assay may assist in such diagnosis.
我们采用酶联免疫吸附测定法来定量检测子宫内膜异位症患者血清中的癌抗原CA - 125。103例未经治疗的子宫内膜异位症患者的CA - 125浓度显著（P小于0.005）高于31例无疾病证据的对照者：分别为9.1（标准差12.3）与2.2（标准差3.2）任意单位/毫升。接受过治疗的子宫内膜异位症患者的值（2.3，标准差2.6，任意单位/毫升，n = 9）低于未经治疗的患者。未经治疗的子宫内膜异位症不同阶段的CA - 125平均浓度分别为：I期4.8（标准差4.5）、II期7.1（标准差9.9）、III期9.8（标准差13.2）和IV期10.8（标准差13.0）任意单位/毫升。对照者与各阶段之间的差异具有统计学意义（所有阶段：P小于0.05）。我们还检测了对照组和未经治疗的子宫内膜异位症患者在月经期（A组）和非月经期（B组）采集的血清。本测定法对子宫内膜异位症患者血清中CA - 125浓度的检测效力在B组高于A组。显然，通过本测定法检测血清中的CA - 125可能有助于此类诊断。
